Skip to main content
. 2017 Jun 29;12(6):e0178325. doi: 10.1371/journal.pone.0178325

Fig 3.

Fig 3

Fusion PET/CT scans at baseline (A.Pre) and after 4 weeks of therapy with pazopanib in a patient with well-differentiated thyroid. Post-pazopanib scan (B.Post) demonstrates new disease along superomedial margin of RFA site (Patient 2). RFA, Radiofrequency ablation; PET, positron-emission tomography.